JDRF-funded researchers at Oregon Health & Science University (OHSU) and Legacy Health have discovered a liquid glucagon formulation that may be usable in standard diabetes pumps. Such a formulation could broaden the use of glucagon to help prevent hypoglycemia in people with type 1 diabetes (T1D) who are treated with insulin. It could also open a path to future-generation artificial pancreas systems that dispense more than just insulin for optimizing glucose control. "Our previous studies have shown that the injections of small amounts of glucagon prevent hypoglycemia, which is a frequent and serious complication of type 1 diabetes that can lead to seizures, loss of consciousness, and even death," said W. Kenneth Ward, M.D., associate professor of medicine (endocrinology, diabetes, and clinical nutrition) at OHSU School of Medicine and senior scientist at Legacy Health, the two Portland, Oregon-based organizations that collaborated on the study. The research was presented at the American Diabetes Association's (ADA) 72nd Scientific Sessions on Friday, June 8, 2012 and on Sunday, June 10, 2012 in Philadelphia. Dr. Ward continues: "Current forms of glucagon cannot be kept for long periods of time in a portable pump, and therefore could not be used as part of an artificial pancreas system.
Login Or Register To Read Full Story